Bayer Pronounces Publication of Part IV Adempas® (riociguat) Knowledge in The Lancet Respiratory Medication

WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which…

Bayer Declares Publication of Section IV Adempas® (riociguat) Information in The Lancet Respiratory Medication

WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which…